Business Context and Reporting Period
This Form 8-K, dated June 20, 2024, reports the completion of a merger transaction between AVROBIO, Inc. and Tectonic Therapeutic, Inc. Effective June 20, 2024, AVROBIO changed its name to Tectonic Therapeutic, Inc. (the "Company") and adopted the ticker symbol TECX on the Nasdaq Global Market. The transaction involved a 1-for-12 reverse stock split of AVROBIO common stock and the issuance of approximately 5.32 million shares to Tectonic stockholders. The Company is a biotechnology firm focused on therapeutic proteins and antibodies modulating G-protein coupled receptors.
Key Financial Metrics and Capital Structure
- Capital Raised: In a pre-closing financing transaction, Tectonic sold 7,790,889 shares at $12.39908 per share, raising approximately $96.6 million. Additionally, Simple Agreements for Future Equity (SAFEs) converted into 2,752,216 shares at the same price. The aggregate capital raised from these transactions was approximately $130.7 million.
- Share Count: Immediately following the merger, approximately 14,734,323 shares of common stock were issued and outstanding, with approximately 15,371,780 shares on a diluted basis.
- Ownership Structure: Former AVROBIO securityholders own approximately 24.8% of the outstanding shares on a diluted basis. Former Tectonic securityholders (including pre-closing financing investors) own approximately 75.2%.
- Liquidity Outlook: Management anticipates that the Company's cash, cash equivalents, and short-term investments will be sufficient to fund operations into 2026.
- Revenue/Profit: This filing does not provide specific revenue, profit, or cash flow figures for the combined entity; it references unaudited pro forma financial information in Exhibit 99.4 and historical data in the Proxy Statement/Prospectus.
Material Changes and Corporate Actions
- Merger Completion: Tectonic survived as a wholly-owned subsidiary of the renamed AVROBIO (now Tectonic Therapeutic, Inc.).
- Reverse Stock Split: A 1-for-12 reverse stock split was effected to adjust share counts prior to the merger.
- Contingent Value Rights (CVRs): Former AVROBIO stockholders received one CVR for each share held. These rights entitle holders to potential future payments derived from the sale or licensing of specific AVROBIO assets (plato manufacturing platform, AVR-RD-01/02/03 programs, and certain IP), net of expenses. There is no assurance payments will be made.
- Accounting Firm Change: Ernst & Young LLP was dismissed as the independent auditor. Deloitte & Touche LLP, Tectonic's former auditor, was appointed as the new independent registered public accounting firm.
Guidance, Management Commentary, and Risks
- Management Commentary: The Company expects to cease being a "shell company" following the merger. The business focus is now primarily on Tectonic's pipeline of GPCR-targeted biologics.
- Executive Compensation: New CEO Alise Reicin, M.D., received an annual base salary of $620,000 and a target bonus of 55%. Closing option grants were issued to the CEO, CFO, CMO, and directors, with vesting schedules tied to service and, in the CFO's case, specific capital raise and cash runway milestones.
- Risks and Contingencies:
- CVR Uncertainty: CVR holders may receive no payments if the specified assets are not sold or licensed.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks related to product development, regulatory approval, and the ability to raise future capital.
- Going Concern: The prior auditor's report for AVROBIO for the year ended December 31, 2022, contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern (prior to this merger).
Investor Verification Checklist
- Verify the terms and potential payout triggers of the Contingent Value Rights (CVRs) in Exhibit 10.1.
- Review the unaudited pro forma financial information in Exhibit 99.4 to understand the combined entity's financial position.
- Confirm the cash runway projections and the specific milestones required for the CFO's performance-based option vesting.
- Check the Proxy Statement/Prospectus (filed May 3, 2024) for detailed risk factors and historical financial data for both AVROBIO and Tectonic.
- Monitor the trading status of the new ticker symbol "TECX" on the Nasdaq Global Market.